Jump to Main Contents
国立がん研究センター 中央病院

Home > About NCCH > Message from the Director

Message from the Director

Toshirou Nishida, M.D., Ph.D.

Since its establishment in 1962, the National Cancer Center Hospital (NCCH) has cooperated with patients and society to realize a world in which we could overcome cancer, and cancer patients could live with cancer with peaceful minds. Nowadays, one in two Japanese will potentially suffer from cancer in their lifetime, and cancer is an illness affecting even the working generation. The NCCH has been providing world-class medical treatment as a cancer-hub hospital in Japan, and has been developing cutting-edge treatments that are more effective and less toxic. A variety of cancer policies and research have been carried out up until now, and treatment outcomes are generally and certainly improving, but cancer still remains a dangerous illness that is difficult to defeat.

As Japan's leading hospital for cancer treatment, the NCCH has propagated the newest cancer treatments throughout Japan and all over the world, and has nurtured many outstanding specialist healthcare providers, including physicians, nurses, and pharmacists. At the same time, the NCCH has not only conducted clinical trials of the world's highest quality and quantity ourselves, but has also supported the clinical research of other hospitals and institutions as a Core Clinical Research Hospital, and is the Hospital selected for the Global Clinical Trial Development Project. Now, cancer medicine is currently in a paradigm shift to move towards precision medicine based on individual genome information. We have expanded the CLIA-compatible NGS Lab (SCI-Lab), and have prepared to provide precision medicine for cancer patients.

Rare and refractory cancers, which companies and universities may not study, frequently have no established diagnostic criteria and treatment, and medical information is also lacking in regards to these cancers. The NCCH Rare Cancer Center has provided more accurate and more updated medical information, as well as reliable high-quality medicines, to patients and families faced with rare cancers. In addition, we have started the “MASTER KEY Project”, a basket and umbrella trials for rare cancer and rare fractions, and are developing effective and safe treatments for unfulfilled medical needs.

There is more to an illness such as cancer than just being "sick". There is also significant suffering and anxiety, and problems that arise and affect daily activities and employment. At our Hospital, we are providing the required support to alleviate or eliminate such suffering of patients and their families from cancer, in addition to treating cancer. We also investigate and develop the best ways to provide such support. For example, we have established the Supportive Care Development Center, on the 8th floor of the hospital, to provide medical and supportive care to improve the quality of life (QOL) of cancer patients. In an unconventional atmosphere, the medicine and care which patients really need is being provided by multimodal and multidisciplinary teams to contribute towards improvement of patient QOL and survival. At the same time, we are establishing evidence-based supportive care medicine through several projects conducted by J-Support (Japan Supportive, Palliative and Psychosocial Oncology Group). As healthcare providers alone cannot accomplish this kind of therapeutic development, patients and medical staff work together to create even better future treatments for cancer.

All employees will continue in our aspirations to provide reliable medical staff and an outstanding hospital for our patients, and will remain engaged in our goal to provide the world's best treatment, and as much as possible to conduct the most cutting-edge research and development.

I ask for your kind support and advice.

Dr. Toshirou NISHIDA, M.D., Ph.D.
Director
National Cancer Center Hospitall